Comparative study of the efficacy and safety of Abexol (suspension versus tablets) in patients with gastrointestinal symptoms.

Autor:	González AH; National Institute of Gastroenterology, Havana, Cuba., Travieso JCF; National Centre for Scientific Research, Havana, Cuba., Casas YH; National Institute of Gastroenterology, Havana, Cuba., González SB; National Institute of Gastroenterology, Havana, Cuba., Morales MLAC; National Institute of Gastroenterology, Havana, Cuba., Batallie EF; National Institute of Gastroenterology, Havana, Cuba., Carralera AR; National Institute of Gastroenterology, Havana, Cuba., Nuñez YR; National Centre for Scientific Research, Havana, Cuba., Castaño SM; National Centre for Scientific Research, Havana, Cuba., García MR; National Clinical Trials Coordinators Centre, Havana, Cuba., Kaba DMR; National Clinical Trials Coordinators Centre, Havana, Cuba.
Jazyk:	angličtina
Zdroj:	The Korean journal of internal medicine [Korean J Intern Med] 2024 Jan; Vol. 39 (1), pp. 57-67. Date of Electronic Publication: 2023 Nov 30.
DOI:	10.3904/kjim.2023.123
Abstrakt:	Background/aims: Abexol is a mixture of primary aliphatic alcohols purified from beeswax (Apis mellifera), that produces anti-inflammatory, antioxidant and gastroprotective effects, as well as it is safe and well tolerated. To investigate and compare the efficacy and safety of Abexol (suspension versus tablets) in patients with gastrointestinal symptoms. Methods: Monocentric study, open-label, randomized design, with two parallel groups receiving Abexol tablets (150 mg/d) or Abexol suspension (75 mg/d) for 8 weeks. Primary efficacy variable (significant improvement in the total score of Gastrointestinal Symptom Rating Scale [GSRS]). Significant reduction in the intensity of the gastrointestinal-symptoms and the reduction in the consumption of antacids are considered secondary efficacy variable. Short form-36 (SF-36) quality of life questiongenonaire was evaluated as collateral variable. Data were analyzed as per intention to treat. Results: A significantly decrease in the overall score of the survey was observed with respect to the baseline level (p < 0.001) of 81.4% in the Abexol suspension group and 77.9% in the Abexol tablets group. At the end of the trial, most gastrointestinal- symptoms disappeared or reduced significantly. The frequency of consumption of neutralizing antacids was low. The significantly improvement in the perception of the state of health obtained in the Abexol is in correspondence with the improvement achieved in some of the components evaluate in the SF-36 questionnaire. Both treatments were safe and well tolerated. Conclusion: Abexol suspension showed efficacy and safety similar to Abexol tablets in patients with gastrointestinal symptoms, but using half the dose.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu